Sign in

AUPH on Nasdaq

Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people.1 It is headquartered in Edmonton, Canada.1 Its shares trade on Nasdaq under the symbol AUPH.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Intercept Pharmaceuticals, Xeris Biopharma Holdings, Inc. or Harrow Health, or pick any stock.

  • TickerAUPH on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersEdmonton, Canada1
  • Business address#140, 14315 - 118 Avenue, Edmonton, A0 T5L 4S62
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

37.1%Operating margin5
101.5%Net margin5
20.4%Revenue growth, 20255
49.4%Return on equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 96% of the revenue Aurinia Pharmaceuticals Inc. broke down this way in fiscal 2025.

  1. Product$271.3M596%up 26% from 2024
  2. License, Collaboration and Royalty Revenue$11.7M54%down 38% from 2024
Products and services by year
Products and services202320242025
Product$158.5M$216.2M$271.3M
License, Collaboration and Royalty Revenue$17.0M$18.9M$11.7M

Regions

United States brought in 93% of the revenue Aurinia Pharmaceuticals Inc. broke down this way in fiscal 2025.

  1. United States$263.8M593%up 26% from 2024
  2. Japan$19.2M57%down 23% from 2024
Regions by year
Regions202320242025
United States$158.0M$210.1M$263.8M
Japan$17.6M$25.0M$19.2M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue6¢$32.7M
  • Research and development6¢$32.5M
  • Income tax33¢$173.0M
  • Profit55¢$287.2M

Out of $283.1M in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Share buybacks72¢$98.2M
  • Kept or used elsewhere28¢$37.5M

Out of $135.7M of cash from operations.5

Financial statements

Revenue67895$283.1M in 2025+88911% since 2019
0$100.0M$200.0M$300.0M2019: $318.0K$318.0K20192020: $50.1M$50.1M2020+15660%2021: $45.6M$45.6M2021−9%2022: $134.0M$134.0M2022+194%2023: $175.5M$175.5M2023+31%2024: $235.1M$235.1M2024+34%2025: $283.1M$283.1M2025+20%
Operating income67895$104.9M in 2025
-$200.0M-$100.0M0$100.0M$200.0M2019: -$90.9M-$90.9M20192020: -$104.3M-$104.3M2020+15%2021: -$180.7M-$180.7M2021+73%2022: -$111.5M-$111.5M2022−38%2023: -$91.7M-$91.7M2023−18%2024: -$4.7M-$4.7M2024−95%2025: $104.9M$104.9M2025
Net income67895$287.2M in 2025
-$200.0M0$200.0M$400.0M2019: -$88.4M-$88.4M20192020: -$102.7M-$102.7M2020+16%2021: -$181.0M-$181.0M2021+76%2022: -$108.2M-$108.2M2022−40%2023: -$78.0M-$78.0M2023−28%2024: $5.8M$5.8M20242025: $287.2M$287.2M2025+4893%

Every line of the income statement as filed: the last 3 fiscal years (annual) or 8 quarters (quarterly), latest first.5

Period ending2025-12-312024-12-312023-12-31
Total revenue$283.1M$235.1M$175.5M
Cost of revenue$32.7M$28.2M$14.1M
Selling, general and administrative$101.8M$172.0M$195.0M
Research and development$32.5M$20.8M$49.6M
Restructuring$1.6M$23.1M$0
Other expense (income), net$9.5M-$4.3M$8.4M
Total operating expenses$178.1M$239.8M$267.2M
Income (loss) from operations$104.9M-$4.7M-$91.7M
Interest income$13.6M$17.0M$17.0M
Interest expense-$4.3M-$4.8M-$2.8M
Net income (loss) before income taxes$114.2M$7.4M-$77.5M
Income tax (benefit) expense-$173.0M$1.7M$551.0K
Net income (loss)$287.2M$5.8M-$78.0M
Unrealized gain on available-for-sale securities$48.0K$83.0K$331.0K
Comprehensive income (loss)$287.2M$5.8M-$77.7M
Basic (in usd per share)$2.14$0.04-$0.54
Diluted (in usd per share)$2.07$0.04-$0.54
Basic (in shares)134.4M shares143.1M shares143.2M shares
Diluted (in shares)138.7M shares146.2M shares143.2M shares

Compare Aurinia Pharmaceuticals Inc. with another company

Corporate structure

Aurinia Pharmaceuticals Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Aurinia Pharmaceuticals Inc.

  • ILJIN SNT Co., Ltd. Filed SCHEDULE 13D/A on Aurinia Pharmaceuticals Inc., latest Aug 26, 2026 (7 filings since Mar 3, 2022)
  • TANG CAPITAL MANAGEMENT LLC Filed SCHEDULE 13D/A on Aurinia Pharmaceuticals Inc., latest Jun 4, 2026 (5 filings since Sep 12, 2024)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Aurinia Pharmaceuticals Inc., latest Feb 14, 2025 (3 filings since Feb 14, 2024)
  • BlackRock Filed SC 13G/A on Aurinia Pharmaceuticals Inc., latest Feb 12, 2024 (2 filings since Feb 7, 2023)
  • Deep Track Capital, LP Filed SC 13G/A on Aurinia Pharmaceuticals Inc., latest Feb 14, 2023 (2 filings since Oct 28, 2022)
  • HealthCor Management, L.P. Filed SC 13G/A on Aurinia Pharmaceuticals Inc., latest Feb 14, 2022
  • Aurinia Pharmaceuticals Inc. Edmonton, Canada
    • Aurinia Pharma U.S., Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aurinia Pharmaceuticals Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$5.3M5 Dec 31, 2025$5.3M5 Dec 31, 20240%
Accumulated depreciation$3.2M5 Dec 31, 2025$2.5M5 Dec 31, 2024+24.5%
Property and equipment, net$2.1M5 Dec 31, 2025$2.7M5 Dec 31, 2024−22.7%
Finance-lease assets$73.9M5 Dec 31, 2025$92.1M5 Dec 31, 2024−19.8%
Operating-lease assets (leased space)$3.6M5 Dec 31, 2025$4.1M5 Dec 31, 2024−11.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$80.2M5 Dec 31, 2025$83.4M5 Dec 31, 2024−3.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$20.4M5 Dec 31, 2025$20.1M5 Dec 31, 2024+1.3%
Accumulated amortization$16.6M5 Dec 31, 2025$15.8M5 Dec 31, 2024+5.4%
Finite-lived intangibles, net$3.8M5 Dec 31, 2025$4.4M5 Dec 31, 2024−13.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$45.7M5 Dec 31, 2025$39.2M5 Dec 31, 2024+16.5%
Raw materials$658.0K5 Dec 31, 2025$1.7M5 Dec 31, 2024−61.3%
Work in process$44.7M5 Dec 31, 2025$36.6M5 Dec 31, 2024+21.9%
Finished goods$379.0K5 Dec 31, 2025$903.0K5 Dec 31, 2024−58.0%

Properties, in its own words

We lease 4,375 square feet of office space in Edmonton, Alberta, which serves as our principal executive office. We lease 30,531 square feet of office space in Rockville, Maryland, which serves as our commercial office. We believe these facilities are adequate to meet our current and future needs.

Item 2 of the 10-K filed Feb 26, 2026.4

Leadership

Who has led Aurinia Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Peter Greenleaf2021–2026
  2. Kevin C. Tang2026–now

Chief financial officer

  1. Joseph M. Miller2021–2026
  2. Michael S. Hearne2026–now

Chief operating officer

  1. Matthew Maxwell Donley2025–2026
  2. Ryan Cole2026–now
2025
Board members and other officers (23)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Aurinia Pharma U.S., Inc. Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 19, 20268-K Other events42
  2. Aug 6, 20268-K Results of operations43
  3. Jun 4, 20268-K Shareholder vote44
  4. Jun 2, 2026New chief executive Kevin C. Tang becomes CEO14
  5. May 11, 20268-K Completed an acquisition or sale45
  6. May 7, 20268-K Results of operations46
  7. Apr 3, 20268-K Entered a material agreement; Regulation FD disclosure47
  8. Mar 23, 20268-K Executive or director change48
  9. Feb 26, 20268-K Results of operations49
  10. Nov 4, 20258-K Results of operations50
  11. Jul 31, 20258-K Results of operations; Other events51
  12. Jun 30, 20258-K Other events52
  13. May 15, 20258-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote53
  14. Jan 4, 2021New chief executive Peter Greenleaf becomes CEO15

Calendar

Coming up

  1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.23 a share, on Nov 4, 2025.54

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results43
  2. May 7, 2026Reported quarterly or annual results46
  3. Feb 26, 2026Reported quarterly or annual results49
  4. Nov 4, 2025Reported quarterly or annual results50
  5. Jul 31, 2025Reported quarterly or annual results51
  6. May 12, 2025Reported quarterly or annual results55
  7. Feb 27, 2025Reported quarterly or annual results56
  8. Nov 7, 2024Reported quarterly or annual results57

Drug trials and FDA: recently

  1. Apr 29, 2024FDA approved a new use FDA approved an efficacy supplement for Lupkynis (voclosporin), a new use or patient group (NDA 213716, supplement 4).58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

253 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 46 major events, 132 insider forms, 20 large holders, 34 other. The latest 20:

  1. Sep 11, 20264 EDGAR
  2. Aug 26, 2026SCHEDULE 13D/A EDGAR
  3. Aug 25, 20264 EDGAR
  4. Aug 21, 2026144 EDGAR
  5. Aug 19, 20268-K EDGAR
  6. Aug 6, 202610-Q EDGAR
  7. Aug 6, 20268-K EDGAR
  8. Jun 8, 20264 EDGAR
  9. Jun 8, 20264 EDGAR
  10. Jun 8, 20264 EDGAR
  11. Jun 8, 20264 EDGAR
  12. Jun 5, 2026144 EDGAR
  13. Jun 4, 2026144 EDGAR
  14. Jun 4, 20268-K EDGAR
  15. Jun 4, 2026SCHEDULE 13D/A EDGAR
  16. Jun 2, 2026144 EDGAR
  17. Jun 2, 20264 EDGAR
  18. May 20, 20264 EDGAR
  19. May 20, 20264 EDGAR
  20. May 20, 20264 EDGAR

The 253 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

79 open-market trades by officers, directors and large owners since October 2021: 22 buys and 57 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 10, 2026Robertson Stephen P.Chief Legal OfficerSale11,939$15.95$190.4KForm 4
Aug 21, 2026Robertson Stephen P.Chief Legal OfficerSale20,975$16.97$355.9KForm 4
Jun 2, 2026TANG KEVINChief Executive OfficerBuy206,005$15.28$3.1MForm 4
Jun 1, 2026TANG KEVINChief Executive OfficerBuy343,620$15.28$5.3MForm 4
May 29, 2026TANG KEVINChief Executive OfficerBuy264,981$15.31$4.1MForm 4
Mar 3, 2026TANG KEVINChief Executive OfficerBuy184,208$14.22$2.6MForm 4
Mar 2, 2026TANG KEVINChief Executive OfficerBuy199,353$14.26$2.8MForm 4
Feb 27, 2026TANG KEVINChief Executive OfficerBuy516,439$13.99$7.2MForm 4
Aug 5, 2025TANG KEVINChief Executive OfficerBuy200,000$11.68$2.3MForm 4
Aug 4, 2025TANG KEVINChief Executive OfficerBuy100,000$11.34$1.1MForm 4
Aug 1, 2025Keenan GregSVP, Chief Medical OfficerSale20,000$10.50$210.0KForm 4
Aug 1, 2025TANG KEVINChief Executive OfficerBuy1,000,000$10.12$10.1MForm 4
Mar 7, 2025Keenan GregSVP, Chief Medical OfficerSale8,305$8.23$68.3KForm 4
Mar 4, 2025Greenleaf PeterChief Executive OfficerSale164,947$7.92$1.3MForm 4
Mar 4, 2025Miller Joseph MChief Financial OfficerSale56,154$7.92$444.7KForm 4
Mar 4, 2025Robertson Stephen P.Chief Legal OfficerSale57,607$7.92$456.2KForm 4
Mar 4, 2025Donley Matthew MaxwellChief Operating OfficerSale58,991$7.92$467.2KForm 4
Mar 4, 2025TANG KEVINChief Executive OfficerBuy748,038$7.96$6.0MForm 4
Mar 3, 2025Greenleaf PeterChief Executive OfficerSale195,593$8.00$1.6MForm 4
Mar 3, 2025Keenan GregSVP, Chief Medical OfficerSale12,239$8.00$97.9KForm 4

All 79 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Peter Greenleaf$822.9K$5.9M65
2025Matthew Donley$567.6K$2.2M65
2025Stephen Robertson44$481.9K$2.1M65
2025Joseph Miller$527.0K$2.1M65
2025Gregory KeenanM.D.$516.2K$1.8M65
2024Former ChiefExecutive Officer$822.9K$6.4M65
2024Former Chief Operating Officer$539.3K$2.5M65
2024Former Chief Financial Officer$500.7K$2.3M65
2024Chief Legal OfficerCorporate Secretary and Chief Compliance Officer$471.7K$2.2M65
2024Former Chief Medical Officer$495.2K$1.3M65
2023Former ChiefExecutive Officer$822.9K$10.6M65
2023Former Chief Operating Officer$513.6K$4.6M65
2023Former Chief Financial Officer$500.7K$4.0M65
2023Chief Legal OfficerCorporate Secretary and Chief Compliance Officer$478.7K$3.6M65
2023Former Chief Medical Officer$400.2K$1.5M65

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Tang Capital Management LLC13,044,106$221.4M10.1%+814,606
BlackRock, Inc.8,193,085$139.0M0.0%+347,564
Goldman Sachs Group Inc5,619,401$95.4M0.0%+4,185,893
NEA Management Company, LLC3,969,834$67.4M4.2%No change
Two Sigma Investments, LP3,467,514$58.8M0.0%+38,809
Arrowstreet Capital, Limited Partnership3,264,062$55.4M0.0%−20,306
State Street Corp2,589,615$43.9M0.0%+62,516
Morgan Stanley2,308,244$39.2M0.0%+75,696
Marshall Wace, Llp2,044,007$34.7M0.0%+169,410
Geode Capital Management, LLC1,701,152$28.9M0.0%+165,143
Renaissance Technologies LLC1,548,035$26.3M0.0%−115,800
D. E. Shaw & Co., Inc.1,408,456$23.9M0.0%−164,527
Vanguard Portfolio Management LLC1,359,028$23.1M0.0%+102,667
Jacobs Levy Equity Management, Inc1,231,516$20.9M0.1%+134,327
Jupiter Asset Management Ltd1,094,475$18.6M0.1%+291,056
Nomura Holdings Inc978,602$16.6M0.1%+9,692
Aqr Capital Management LLC948,751$16.1M0.0%−59
Northern Trust Corp863,567$14.7M0.0%+39,462
Nuveen, LLC812,915$13.8M0.0%+159,491
Jupiter Topco LLC602,195$10.2M0.0%New
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main596,618$10.1M0.0%−18,473
Prudential Financial Inc582,345$9.9M0.0%−8,265
O'shaughnessy Asset Management, LLC567,492$9.6M0.0%+153,473
Hillsdale Investment Management Inc.550,900$9.3M0.2%+341,000
Qube Research & Technologies Ltd479,970$8.1M0.0%−450,661

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Aurinia Pharmaceuticals Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAurinia Pharmaceuticals Inc.1
  • CIK0001600620
  • Employer ID (EIN)98-12317634
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
  • Incorporated inCanada4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address#140, 14315 - 118 Avenue, Edmonton, A0 T5L 4S61
  • Phone250-744-24871
  • Shares outstanding133,051,168 as of Aug 5, 202611
  • Public float$1.0B as of Jun 30, 20254
  • AuditorPricewaterhouseCoopers LLP, Edmonton, Canada PCAOB ID 271; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceFeb 28, 20141
  • Filings613 in all: 6-K (204), 4 (150), 8-K (55), 3 (29), SC 13D/A (20), 10-Q (17), SUPPL (16), SC 13G (15)1
    All 38 form types

    SC 13G/A (13), DEFA14A (9), S-8 (8), 144 (7), PX14A6G (7), 10-K (6), 40-F (6), DEF 14A (6), SCHEDULE 13D/A (6), SC 13D (5), 4/A (4), F-X (4), EFFECT (3), F-10 (3), F-10/A (3), 10-K/A (2), 8-K/A (2), 40-F/A (1), 40FR12B (1), 40FR12B/A (1), 6-K/A (1), ARS (1), CERTNAS (1), D (1), FWP (1), PRE 14A (1), S-3ASR (1), SC TO-T (1), SC TO-T/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 21, 2026
    Latest 8-K (8-K) Aug 19, 2026

Securities registered for trading

ClassSymbolExchange
Common shares, no par valueAUPHThe Nasdaq Global Market LLC

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Aurinia Pharmaceuticals Inc. names in Item 1A of its 10-K filed Feb 26, 2026: 32 risks under these headings, as written.4

  • RISKS RELATED TO COMMERCIALIZATION
  • We are substantially dependent on the commercial success of LUPKYNIS.
  • Product liability or other lawsuits against us could cause us to incur substantial liabilities and reduce LUPKYNIS sales.
  • The commercial success of LUPKYNIS in certain ex-U.S. territories is dependent on the fulfillment of contractual obligations under our collaboration and licensing agreement and commercial supply agreement.
  • The commercial success of LUPKYNIS is dependent on pricing regulations and/or third-party coverage and reimbursement policies.
  • If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines.
  • RISKS RELATED TO PATENTS AND PROPRIETARY TECHNOLOGY
  • LUPKYNIS’s market exclusivity periods will depend on the validity and enforceability of issued and pending patents covering LUPKYNIS.
  • If our products or our product candidates infringe the rights of others, we could be subject to expensive litigation, become liable for substantial damages, be required to obtain licenses from others or be prohibited from selling our products or product candidates altogether.
  • Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
  • We may not be able to protect the confidentiality of our trade secrets.
  • RISKS RELATED TO FINANCIAL POSITION
The other 23 risks
  • Our overall financial performance may not meet our expectations.
  • Our ability to use our net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations. We may also be subject to other potential tax consequences.
  • RISKS RELATED TO DRUG DEVELOPMENT AND REGULATORY APPROVAL
  • Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies of aritinercept may not be predictive of future study results.
  • Results from studies of aritinercept may not be sufficient to obtain regulatory approvals to market it on a timely basis, if at all.
  • Our development of aritinercept may be delayed or halted.
  • Compliance with ongoing post-marketing obligations for LUPKYNIS may uncover new safety information that could give rise to a product recall, updated warnings or other regulatory actions.
  • Failure to obtain regulatory approval in international jurisdictions would prevent our products, our product candidates or any other products we or our current or future out-licensees may develop from being marketed abroad.
  • RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES
  • The commercial success of LUPKYNIS and the clinical success of aritinercept will depend on our ability to obtain an uninterrupted supply from our contract manufacturers.
  • We rely on third parties to provide certain services relating to our commercial distribution, clinical studies and other activities. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may face delays in the studies, regulatory submissions, regulatory approval or commercialization of aritinercept, or the commercialization of LUPKYNIS.
  • RISKS RELATED TO GOVERNMENT REGULATION
  • We are subject to various federal, state and foreign laws and regulations governing the health care industry that could result in substantial penalties for noncompliance.
  • Drugs approved by the FDA, EC and/or other regulatory agencies are subject to ongoing regulation.
  • Changes or developments in U.S. economic laws or policies, including the reaction of other countries thereto, may have a material adverse effect on our business.
  • RISKS RELATED TO OWNERSHIP OF OUR COMMON SHARES
  • The volume and trading price of our common shares may fluctuate significantly, and you may lose all or part of your investment.
  • We have never paid a dividend on our common shares.
  • Our capital requirements and our potential need for, and ability to obtain, additional financing are uncertain. If we need to obtain additional financing in the future, such financing could result in dilution to your investment, adversely affect the trading price of our common shares and/or create future operating and financial restrictions.
  • There can be no assurance that we will continue to repurchase Common Shares or that we will repurchase Common Shares at favorable prices.
  • GENERAL RISK FACTORS
  • Our ability to hire and retain key employees is uncertain.
  • Our employees, consultants, contract manufacturing organizations, principal investigators, and clinical research organizations may engage in misconduct, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
  • Business interruptions resulting from geopolitical actions, natural disasters, public health crises or other catastrophic events could have an adverse impact on our business.
  • You may be unable to enforce actions against us, or certain of our officers under U.S. laws.
  • Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
  • Use of hazardous materials might expose us to risk in the form of damages.

Legal proceedings

From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

On November 2, 2025, we and our wholly owned subsidiary, Aurinia Pharma U.S., Inc., filed a complaint alleging defamation and injurious falsehood against Dr. George Tidmarsh in the U.S. District Court for the District of Maryland. The complaint alleges that Dr. Tidmarsh personally made false statements regarding voclosporin. We are seeking monetary damages, punitive damages, court costs, and any other relief the court deems appropriate.

In February and March 2025, we received a Notice Letter from each of Hikma Pharmaceuticals USA Inc., Lotus Pharmaceutical Co. Ltd., Galenicum Health S.L.U., Zydus Pharmaceuticals (USA) Inc., Teva Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Inc., DifGen Pharmaceuticals LLC and Sandoz Inc. advising that each company had submitted an ANDA to the FDA seeking authorization to manufacture, use or sell a generic version of LUPKYNIS in the U.S., prior to the expiry of the 2037 Patents, which are listed in the FDA's Orange Book. Each Notice Letter alleges that the 2037 Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in the ANDA.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65